NASDAQ:IOVA - Iovance Biotherapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Iovance Biotherapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $23.88 +0.14 (+0.59 %) (As of 01/17/2020 04:00 PM ET) Add Compare Today's Range$23.31Now: $23.88▼$24.1050-Day Range$22.81MA: $26.25▼$29.4152-Week Range$8.26Now: $23.88▼$29.67Volume1.22 million shsAverage Volume1.48 million shsMarket Capitalization$3.01 billionP/E RatioN/ADividend YieldN/ABeta2.07 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IOVA Previous Symbol CUSIPN/A CIK1425205 Webhttp://www.iovance.com/ Phone650-260-7120Debt Debt-to-Equity Ratio0.02 Current Ratio10.61 Quick Ratio10.61Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.78 per share Price / Book6.32Profitability EPS (Most Recent Fiscal Year)($1.27) Net Income$-123,580,000.00 Net MarginsN/A Return on Equity-40.29% Return on Assets-37.56%Miscellaneous Employees88 Outstanding Shares126,195,000Market Cap$3.01 billion Next Earnings Date2/26/2020 (Estimated) OptionableOptionable Receive IOVA News and Ratings via Email Sign-up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:IOVA Rates by TradingView Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions What is Iovance Biotherapeutics' stock symbol? Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA." How were Iovance Biotherapeutics' earnings last quarter? Iovance Biotherapeutics Inc (NASDAQ:IOVA) issued its earnings results on Monday, November, 4th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.01. View Iovance Biotherapeutics' Earnings History. When is Iovance Biotherapeutics' next earnings date? Iovance Biotherapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Iovance Biotherapeutics. What price target have analysts set for IOVA? 12 Wall Street analysts have issued 12 month target prices for Iovance Biotherapeutics' stock. Their forecasts range from $27.00 to $38.00. On average, they anticipate Iovance Biotherapeutics' share price to reach $31.73 in the next twelve months. This suggests a possible upside of 32.9% from the stock's current price. View Analyst Price Targets for Iovance Biotherapeutics. What is the consensus analysts' recommendation for Iovance Biotherapeutics? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iovance Biotherapeutics. What are Wall Street analysts saying about Iovance Biotherapeutics stock? Here are some recent quotes from research analysts about Iovance Biotherapeutics stock: 1. According to Zacks Investment Research, "Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. " (1/14/2020) 2. HC Wainwright analysts commented, "Our thesis on TILs stands strong. In accordance with our thesis, showing efficacy in solid tumors beyond melanoma continues to represent a game changer for Iovance and, on a broader look, we continue to view this company as a viable takeout candidate for Big Pharma. We would like to reiterate that, apart from academic-based TILs therapies such as NCI and MD Anderson, Iovance is the only biotech that is developing a commercial TIL product to treat a variety of tumors and patients using the predefined cryopreserved 22-day manufacturing strategy." (7/2/2019) 3. Chardan Capital analysts commented, "We therefore expect to see a similar rate in the registration-directed Cohort 4 which is currently enrolling." (5/31/2019) Has Iovance Biotherapeutics been receiving favorable news coverage? News stories about IOVA stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Iovance Biotherapeutics earned a news impact score of -3.6 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Iovance Biotherapeutics. Are investors shorting Iovance Biotherapeutics? Iovance Biotherapeutics saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 14,830,000 shares, a drop of 9.5% from the December 15th total of 16,390,000 shares. Based on an average daily volume of 1,220,000 shares, the short-interest ratio is currently 12.2 days. Currently, 12.9% of the company's shares are sold short. View Iovance Biotherapeutics' Current Options Chain. Who are some of Iovance Biotherapeutics' key competitors? Some companies that are related to Iovance Biotherapeutics include Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), bluebird bio (BLUE), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO) and Acceleron Pharma (XLRN). What other stocks do shareholders of Iovance Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Portola Pharmaceuticals (PTLA), Applied Materials (AMAT), Immunomedics (IMMU), Kadmon (KDMN), CA (CA), BlackRock (BLK), Seattle Genetics (SGEN), Bristol-Myers Squibb (BMY), Amarin (AMRN) and Heron Therapeutics (HRTX). Who are Iovance Biotherapeutics' key executives? Iovance Biotherapeutics' management team includes the folowing people: Dr. Maria Fardis, CEO, Pres & Director (Age 51)Mr. Timothy E. Morris, CFO, Principal Accounting Officer, Corp. Sec. & Treasurer (Age 57)Dr. Frederick G. Vogt Ph.D., Esq., Gen. Counsel (Age 45)Mr. Howard B. Johnson, Sr. VP of Corp. Devel., Alliance Management & Program Management (Age 59)Dr. Elma S. Hawkins Ph.D., MBA, Advisor to the Board (Age 62) Who are Iovance Biotherapeutics' major shareholders? Iovance Biotherapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.43%), Rhenman & Partners Asset Management AB (0.38%), Tocqueville Asset Management L.P. (0.05%) and Evanson Asset Management LLC (0.01%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Institutional Ownership Trends for Iovance Biotherapeutics. Which major investors are selling Iovance Biotherapeutics stock? IOVA stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Tocqueville Asset Management L.P., Rhenman & Partners Asset Management AB and Evanson Asset Management LLC. View Insider Buying and Selling for Iovance Biotherapeutics. How do I buy shares of Iovance Biotherapeutics? Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Iovance Biotherapeutics' stock price today? One share of IOVA stock can currently be purchased for approximately $23.88. How big of a company is Iovance Biotherapeutics? Iovance Biotherapeutics has a market capitalization of $3.01 billion. The biotechnology company earns $-123,580,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Iovance Biotherapeutics employs 88 workers across the globe.View Additional Information About Iovance Biotherapeutics. What is Iovance Biotherapeutics' official website? The official website for Iovance Biotherapeutics is http://www.iovance.com/. How can I contact Iovance Biotherapeutics? Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected] MarketBeat Community Rating for Iovance Biotherapeutics (NASDAQ IOVA)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 437 (Vote Outperform)Underperform Votes: 241 (Vote Underperform)Total Votes: 678MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote "Outperform" if you believe IOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IOVA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2020 by MarketBeat.com StaffFeatured Article: Learning About the VIX - Volatility Index
